The global actinic keratosis treatment market size is expected to be worth around US$ 10.12 billion by 2030, according to a new report by Vision Research Reports.
The global actinic keratosis treatment market size is expected to be worth around US$ 10.12 billion by 2030, according to a new report by Vision Research Reports.
The global actinic keratosis treatment market size was valued at US$ 7.8 billion in 2020 and is anticipated to grow at a CAGR of 7.3% during forecast period 2021 to 2030.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38605
Growth Factors
The increasing prevalence of the disease coupled with an increasing geriatric population and rising awareness about the disease are factors expected to drive the growth over the forecast period. For instance, in the U.S. and Europe, the prevalence of the disease ranges from 11 to 26%, due to which it is the most commonly treated dermatologic disease in the outpatient setting in the U.S. Moreover, the prevalence is highest in Australia with an estimation of 37 to 55% in adults aged 40 years and above. However, the outbreak of COVID-19 has affected the market adversely.
Report Coverage
|
Report Scope |
Details |
|
Market Size |
USD 10.12 billion by 2030 |
|
Growth Rate |
CAGR of 7.3% From 2021 to 2030 |
|
Base Year |
2021 |
|
Historic Data |
2017 to 2020 |
|
Forecast Period |
2021 to 2030 |
|
Segments Covered |
Therapy, Drug class, End-use |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
|
Companies Mentioned |
Almirall, S.A.; Biofrontera AG; Bausch Health Companies, Inc.; LEO Pharma A/S; Sun Pharmaceutical Industries Ltd.; Novartis AG; GALDERMA; Hill Dermaceuticals, Inc. |
Report Highlights
The surgical therapy segment dominated the global market in 2020 with a revenue share of more than 67%. The segment is anticipated to maintain its dominance over the forecast period. The high penetration of cryotherapy for the treatment of AK will drive the segment growth. This is also called field therapy and has a low associated risk of scarring. The photodynamic therapy segment is anticipated to grow at a CAGR of 7.10% over the forecast period.
The nucleoside metabolic inhibitors drug class segment led the global market in 2020 with a revenue share of over 32%. The growth was driven by the strong commercial performances of Carac, Efudex, and Fluoroplex. Moreover, increasing awareness about diagnostics and treatment strategies for this disease has driven the widespread adoption of field-directed treatments, such as 5-fluorouracil.
The photo-enhancers segment is estimated to witness the fastest CAGR during the forecast period. Photodynamic therapy is gaining ground and is expected to positively impact the market growth of photo-enhancers.
The photo-enhancers segment is estimated to witness the fastest CAGR during the forecast period. Photodynamic therapy is gaining ground and is expected to positively impact the market growth of photo-enhancers.
The home care segment is anticipated to grow at the fastest CAGR over the forecast period. Increasing adoption of topical therapies, availability of OTC drugs, and patient convenience are factors driving the segment growth over the forecast period.
North America accounted for the highest revenue share of more than 42% of the global market in 2020. It is anticipated to maintain its dominance over the forecast period.
Asia Pacific is estimated to grow at the fastest CAGR over the forecast period due to an increase in the treatment rate of the disease, rising consumer disposable income, and high disease prevalence in certain countries, such as Australia and New Zealand.
Market Drivers
Rise in the Adoption of Minimally Invasive Treatments.
There is a rapid increase in the adoption of minimally invasive treatments owing to demand for fast recovery; and rise in the inclination towards cost-effectiveness for treating squamous cell carcinoma. Healthcare providers in developed nations are offering prescription coverage for selected procedures for actinic keratosis, which is further propelling the growth of the Actinic Keratosis Treatment Market.
Increase in the Government Initiatives.
The governments across the world are focusing on making healthcare facilities more affordable by implementing various initiatives. These initiatives have increased the number of patients participating in actinic keratosis treatment, which is propelling the growth of the Actinic Keratosis Treatment Market. Moreover, the presence of attractive rebate programs is further driving the growth of the Actinic Keratosis Treatment Market.
Market Challenges
High Cost of Actinic Keratosis Treatment.
The key players across the globe are increasing their investments to develop new drugs for the treatment of actinic keratosis. However, high cost of actinic keratosis treatments and complications involved with the care modules currently available is one of the major factors that is estimated to reduce the growth of the Actinic Keratosis Treatment Market.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38605
Key Market Trends
Topical Medications Segment is Expected to Hold a Major Market Share in the Actinic Keratosis Treatment Market
The topical medications segment holds a significant share in the actinic keratosis treatment market and is anticipated to show a similar trend over the forecast period due to the easy availability of products, high target specificity, and a lower risk of scarring. Some of the United States Food and Drug Administration (FDA) approved medications for treating actinic keratoses are topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and combination treatment with drugs.
Rising incidence of baldness, skin wrinkling and sunburn patches have led to increased actinic keratosis cases. Those from Australia and New Zealand in particular often showed more adverse effects of sun exposure than patients from other regions. According to the study "Actinic Keratosis" updated in July 2021, the prevalence of actinic keratosis is higher in countries closer to the equator. Because of its proximity to the equator, Australia's prevalence rate of actinic keratosis is close to 60%. (in addition to its sizable White population). In comparison, in a non-equatorial location such as the United States, the prevalence of actinic keratosis is around 20%. Therefore, the growing prevalence rate of actinic keratosis among people is expected to increase the demand for effective treatment such as topical medications, in turn, fueling the target segment growth in the studies period.
Furthermore, actinic keratosis is considered precancerous because a cutaneous squamous cell carcinoma may arise from actinic keratosis. As the number of actinic keratoses increases the chance of developing squamous cell carcinoma increases. Thus, as the prevalence of actinic keratosis has increased, there is an urgency to adopt the most cutting-edge treatments, which leads to a large increase in the number of new drugs in the pipeline. For instance, in February 2021, Almirall, S.A. launched Klisyri (tirbanibulin), a topical treatment for actinic keratosis (AK) of the face and scalp. Klisyri was approved by the United States Food and Drug Administration (FDA) in December 2020.
Key Players
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- GALDERMA
- Hill Dermaceuticals, Inc.
- Viatris Inc.
- Mylan N.V.
- Bausch Health Companies, Inc.
- LEO Pharma A/S
- Almirall, S.A.
- Biofrontera AG
- 3M
Market Segmentation
- Therapy
- Topical
- Surgery
- Photodynamic Therapy
- Drug Class
- Nucleoside Metabolic Inhibitor
- NSAIDs
- Immune Response Modifiers
- Photoenhancers
- Others
- End-use
- Hospitals
- Private Clinics
- Homecare
- Others
- Regional
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38605
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://qyresearchmedical.com/